Exelixis | EXEL - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
Akebia Therapeutics 362.52M 357.69M 2026-03
Amgen USD 657M 4M 2026-03
AstraZeneca USD 484M 181M 2025-12
Bayer EUR 675M 87M 2025-12
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Bristol-Myers Squibb USD 411M 21M 2026-03
Cytokinetics USD 33.34M 3M 2026-03
Eisai JPY 1.55B 117M 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Exelixis USD 23.4M 3.9M 2023-09
Genmab DKK 10M 27M 2025-12
Glaxosmithkline GBP 192.73M 14.79M 2026-03
Incyte USD 569K 13K 2026-03
Ionis Pharmaceuticals USD 17M 1000K 2026-03
MacroGenics USD 4.89M 1.55M 2026-03
Merck USD 479M 67M 2026-03
Moderna USD 11.49B 36B 2026-03
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 343M 39M 2026-03
Pfizer USD 671M 40M 2026-03
Puma Biotechnology USD 3.37M 11K 2024-06
Sanofi EUR -25M 99.78M 2025-12
Takeda JPY 43.65B 79.98B 2026-03
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
Xencor USD 4.7M 2.65M 2026-03